Ken Griffin Context Therapeutics Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$0.92 - $1.38 $771 - $1,157
-839 Reduced 5.28%
15,041 $20,000
Q4 2023

Feb 14, 2024
BUY
$0.79 - $1.41 $4,299 - $7,673
5,442 Added 52.14%
15,880 $17,000
Q3 2023

Nov 14, 2023
BUY
$0.9 - $1.59 $9,394 - $16,596
10,438 New
10,438 $15,000

Others Institutions Holding CNTX

# of Institutions
45
Shares Held
56.9M
Call Options Held
0
Put Options Held
0
View Full List

About Context Therapeutics Inc.

CNTX Quotes by TradingView
  • Ticker CNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,966,100
  • Market Cap $17.6M
  • Description
  • Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...
More about CNTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email